OpenAlex
PricingAboutJobs
Log inGet started
Work

Differentiating mTOR inhibitors in renal cell carcinoma

HTML

Year: 2013
Type: review
Source: Cancer Treatment Reviews
DOI: 10.1016/j.ctrv.2012.12.015
Authors: Sumanta K. Pal, David I. Quinn
Institutions: City Of Hope National Medical Center, City of Hope, USC Norris Comprehensive Cancer Center
Language: English

Topic: PI3K/AKT/mTOR signaling in cancer
Subfield: Molecular Biology
Field: Biochemistry, Genetics and Molecular Biology
Domain: Life Sciences
Keywords: mTOR inhibitors, renal cell carcinoma, temsirolimus, everolimus, PI3K/AKT/mTOR signalling, metastatic renal cell carcinoma, pharmacokinetics/pharmacodynamics, treatment sequencing
SDG: Good health and well-being

Open Access status: green

Funders: Novartis Pharmaceuticals Corporation, National Cancer Institute
Award: City of Hope Clinical Oncology Career Research Development Program
OpenAlex ID: W2088813853
FWCI: 0.776
Cites: 105
Cited by: 101
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security